People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| vTv Therapeutics Inc. | — | Pharmaceuticals | Series C | $80.5M | $502.3M | 2024 |
John A. Fry at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John A. Fry on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Meister | 1 | 12 |
| Steven Cohen | 1 | 6 |
| Craig Parker | 1 | 5 |
| John Fry | 1 | 4 |
| Jeffrey Kindler | 1 | 3 |
| Howard Weiner | 1 | 3 |
| Richard L Nelson | 1 | 2 |
| Noel Spiegel | 1 | 2 |
| Rudy Howard | 1 | 2 |
| Paul J. Sekhri | 1 | 2 |
| Paul Savas | 1 | 2 |
| Larry Altstiel | 1 | 1 |
| Keith A. Harris | 1 | 1 |
| Steven J. Tuch | 1 | 1 |
| Srinivas L. Akkaraju | 1 | 1 |
| Raymond A. Cheong | 1 | 1 |
| Fahed L. Al Marzooqi | 1 | 1 |
| Howard L. Weiner | 1 | 1 |
| Stephen Holcombe | 1 | 1 |
| Hersh Kozlov | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.